Johnson Pharmacare Ltd
₹ 0.46
9.52%
05 Oct
2:39 p.m.
About
Johnson Pharmacare Limited, formerly Sun
and Shine Worldwide Limited, is an investment-focused listed company with no demonstrated pharmaceutical operations.
Key Points
- Market Cap ₹ 25.3 Cr.
- Current Price ₹ 0.46
- High / Low ₹ 0.77 / 0.41
- Stock P/E
- Book Value ₹ 0.01
- Dividend Yield 0.00 %
- ROCE -105 %
- ROE -146 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 51.2 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -29.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | -0 | 1 | -0 | 1 | 3 | 3 | -0 | -0 | -0 | 0 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 43 | 43 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -43 | -43 |
| OPM % | -1.1% | -0.0% | 4.0% | 9% | |||||||||
| -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | -2 | -0 | -0 | -13 | -13 | |
| Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 1 |
| Depreciation | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Profit before tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -1 | -0 | -1 | -56 | -57 |
| Tax % | -0% | -0% | -0% | -0% | -0% | -0% | 31% | -3% | -0% | -0% | -0% | ||
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -1 | -0 | -1 | -56 | -57 | |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.02 | -0.00 | -0.01 | -1.01 | -1.03 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -10019% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | -10% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -16% |
| 3 Years: | -30% |
| Last Year: | -146% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 55 | 55 | 55 | 55 | 55 |
| Reserves | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 3 | 2 | 2 | 1 | -55 |
| 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 21 | |
| 0 | 0 | 0 | 0 | 0 | -0 | 1 | 1 | 1 | 1 | 1 | 0 | |
| Total Liabilities | 60 | 59 | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | 54 | 43 | 54 | 54 | 53 | 52 | 52 | 54 | 46 | 46 | 42 | 20 |
| 6 | 16 | 5 | 6 | 7 | 7 | 7 | 6 | 14 | 14 | 16 | 2 | |
| Total Assets | 60 | 59 | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | -11 | 11 | -1 | -1 | 0 | -0 | 5 | -0 | -0 | -2 | -57 | |
| 10 | 11 | -11 | -0 | 1 | 1 | -0 | -5 | -1 | -0 | 3 | 58 | |
| 2 | 0 | -0 | 1 | -0 | -1 | 0 | -0 | 1 | 0 | -1 | -0 | |
| Net Cash Flow | 21 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 |
| Free Cash Flow | 8 | -11 | 11 | -1 | -1 | 0 | -0 | 5 | -0 | -0 | -2 | -57 |
| CFO/OP | -41,350% | 8,385% | -8,200% | 1,417% | 9,300% | -189% | 3,800% | -200% | 25% | 764% | 134% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 807 | 118 | -0 | ||||||||
| Inventory Days | -0 | -0 | -0 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 365 | 807 | 118 | -0 | ||||||||
| Working Capital Days | 1,932 | 2,267 | -9 | -141 | ||||||||
| ROCE % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 0% | 0% | -0% | -0% | -105% |
Documents
Announcements
- Closure of Trading Window
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Pursuant to regulation 47 of LODR, 2015 -Submission of extract of Newspaper Publication for the unaudited financial result for the quarter ended 30th June, 2026.
-
Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations, 2015 For The Quarter Ended On June 30Th, 2026.
- Undertaking confirms Regulation 32 not applicable for quarter ended June 30, 2026.
-
Submission Of Un-Audited Financial Results Of (JOHNSON PHARMACARE LTD) For The Quarter Ended On June 30Th, 2026 And Along With Limited Review Report Thereon.
- Unaudited Q1 FY2026-27 results submitted with limited review report on August 13, 2026.
-
Board Meeting Outcome for Outcome Of Meeting Of Board Held On Thursday, 13Th August, 2026 At Pursuant To Regulation 30 Of
The SEBI (LODR) Regulations, 2015.
- Board approved unaudited Q1 FY2026-27 results on 13 August 2026; Regulation 32 deemed not applicable.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Operational Status:[1][2][3]
a) The company’s recent filings do not
disclose pharmaceutical manufacturing,
product sales, licences, plants, customers
or distribution operations. The FY26 auditor describes the company’s business as investing in shares, while the FY25 Directors’ Report states that the company had no significant business activity.
b) It has no fixed assets, physical inventory
or manufacturing capacity. Its investments
are held through demat account
c) Revenue from operations and other income were both nil in FY24, FY25, F26. Also, FY25 expenses of ₹58.38 lakh consequently translated directly into a net loss.